Article Text

Download PDFPDF
Patients with lupus with COVID-19: University of Michigan experience
  1. Beth Wallace1,2,
  2. Laraine Washer3,
  3. Wendy Marder1,4,
  4. J Michelle Kahlenberg1
  1. 1 Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA
  2. 2 Internal Medicine/Rheumatology, VA Ann Arbor Healthcare System, Ann Arbor, Michigan, USA
  3. 3 Internal Medicine/Infectious Diseases, University of Michigan, Ann Arbor, Michigan, USA
  4. 4 Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, Michigan, USA
  1. Correspondence to Dr J Michelle Kahlenberg, Internal Medicine/Rheumatology, University of Michigan, Ann Arbor, MI 48109, USA; mkahlenb{at}med.umich.edu

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We read with interest the recent report by Mathian et al 1 regarding the clinical course of COVID-19 infection in 17 patients with systemic lupus erythematosus (SLE) under long-term hydroxychloroquine treatment. We report supportive findings in five patients with SLE, contextualised in a larger cohort of patients with rheumatological conditions, from an academic, tertiary-care population.

Between 1 March and 20 April 2020, 31 patients followed at University of Michigan rheumatology clinics were diagnosed with COVID-19 (see online supplementary table 1). Five (16%) of these patients had SLE, four of whom were taking hydroxychloroquine with a median (range) duration of …

View Full Text

Footnotes

  • Twitter @BethIWallace, @Kahlenberglab

  • Contributors All authors drafted and edited the manuscript and approved the final version.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests JMK reports personal fees from AstraZeneca, personal fees from Eli Lilly, personal fees from Boehringer Ingleheim, and grants and personal fees from Bristol Myers Squibb, during the conduct of the study. No other authors have any competing interests to disclose.

  • Patient and public involvement Patients and/or the public were not involved in the design, conduct, reporting or dissemination plans of this research.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Linked Articles